@article {Olayanju1901181, author = {Olayanju, Olatunde and Esmail, Aliasgar and Limberis, Jason and Dheda, Keertan}， title ={含有bedaquiline和delamanid的方案与bedaquiline在耐药结核病患者中的比较}，volume = {55}， number = {1}， location-id = {1901181}， year = {2020}，在耐药结核病(DR-TB)治疗中联合使用delamanid和bedaquiline的数据有限。188bet官网地址目前还没有预期的长期结果数据，包括艾滋病毒感染者的数据。2014年至2018年，我们前瞻性随访了122名南非患者(52.5%艾滋病毒感染)，这些患者均患有耐药结核病，预后不佳。我们比较了接受bedaquiline (n=82)和接受bedaquiline{\textendash}delamanid联合方案(n=40)的结果和安全性。6个月培养转化率无显著差异(92.5% vs 81.8%;P =0.26)和18个月预后良好的比率(63.4\%对67.5\%;P =0.66)，尽管后者的耐药程度更高(至少5种药物耐药率分别为3.7%和22.5%;p=0.001)和更高的治疗前失败率(12.2\% vs 52.5\%治疗前耐多药结核病治疗失败;p < 0.001)。尽管联合治疗组中使用Fridericia公式纠正的QT间期延长的比例更高(比基线时间60 ms (p=0.001)或治疗期间>450 ms (p=0.001))，但两组均无症状病例或停药。 Results were similar in HIV-infected patients.A bedaquiline{\textendash}delamanid combination regimen showed comparable long-term safety compared to a bedaquiline-based regimen in patients with DR-TB, irrespective of HIV status. These data inform regimen selection in patients with DR-TB from TB-endemic settings.A bedaquiline{\textendash}delamanid combination regimen in drug-resistant tuberculosis patients with poor prognostic factors showed comparable efficacy and safety to those in a bedaquiline-based regimen http://bit.ly/32j7Fyo}, issn = {0903-1936}, URL = {//www.qdcxjkg.com/content/55/1/1901181}, eprint = {//www.qdcxjkg.com/content/55/1/1901181.full.pdf}, journal = {European Respiratory Journal} }